Navigation Links
AtriCure Reports Record Second Quarter 2008 Financial Results
Date:8/5/2008

Highlights

-- Record consolidated revenues of $14.9 million

-- Record revenues from domestic MIS products - $5.1 million

-- Record international revenues of $2.3 million - 49% growth

-- Net loss improves 43% to $1.6 million

-- Secured $10 million credit facility - expands capital resources -- Reported MIS procedure times of 60 minutes and hospital stays of two

days or less

WEST CHESTER, Ohio, Aug. 5 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems, today announced record second quarter 2008 revenues of $14.9 million and record revenues for each line of business.

"Based on our encouraging financial trends, available cash and newly secured credit facility, we are well positioned to drive toward profitability," said David J. Drachman, President and Chief Executive Officer. "Importantly, minimally invasive procedure times of 60 minutes and patients discharged from the hospital at two days or less, combined with our reported clinical results are clear indicators of our progress and the large and growing opportunity for our products."

Second Quarter 2008 Financial Results

Revenues for the second quarter of 2008 were a record $14.9 million, a 20.3% increase over the second quarter of 2007 and a sequential increase of 9.8% over the first quarter of 2008. Revenues from domestic open-heart products were a record $7.4 million, an 8.9% increase over second quarter 2007 revenues of $6.8 million and a 7.2% sequential increase. Revenues from domestic minimally invasive products were a record $5.1 million, representing a
'/>"/>

SOURCE AtriCure, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. AtriCure Announces Web Cast and Conference Call of Second Quarter 2008 Financial Results
2. AtriCure Reports First Quarter 2008 Financial Results
3. AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy(TM) Bipolar Ablation System to Treat Atrial Fibrillation
4. AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008
5. eResearchTechnology Reports Second Quarter 2008 Results
6. SuperGen Reports 2008 Second Quarter Financial Results
7. Neurobiological Technologies Reports Receipt of $2.1 Million Royalty Payment for Quarterly Sales of Memantine
8. InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
9. CV Therapeutics Reports 2008 Second Quarter Financial Results
10. Gentiva Reports Strong Second Quarter led by Home Health Segment
11. United Therapeutics Reports Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA ... disease. One of these latent viruses is the Epstein ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... by the theory, a study found that RA patients ... (1). , What is Microcompetition? , Dr. Hanan ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... of high throughput research solutions, today announced that ... companies, has received delivery of Freeslate’s CM ... form screening. , Lupin, headquartered in Mumbai, ... quality, affordable generic and branded formulations and Active ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, ... Foundation, the only national nonprofit organization solely dedicated to ... quality of life for those affected worldwide, will host ... Warrington Country Club in Warrington, Pa. , Each ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider ... major scientific, regulatory, business, and media events in ... , today announced its former associate Virginia Cox , ... office. Virginia Cox re-joins ... Commissioner for the Office of External Affairs at the U.S. ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2
... SAN FRANCISCO, March 16 Medivation, Inc. (Nasdaq: ... and financial results for the fourth quarter and year ended December ... to an equally exciting 2009. We have made excellent progress across ... testing in all of our programs in 2009 -- Dimebon in ...
... 16 TauTaTis, Inc. announces that its lead compound ... process in Alzheimer,s Disease, has been recognized as the ... Disease gene LRRK2 reported to date. Mutations of ... are the most genetic frequent cause of Parkinson,s Disease.TauTaTis, ...
... Provider, Offers Traceability Down to the Unit Level to Secure ... ... Southborough, MA (PRWEB) March 16, 2009 -- PHARMORX ... technology services provider, today announced the availability of its new ...
Cached Biology Technology:Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update 2Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update 3Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update 4Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update 5Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update 6Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update 7Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update 8TauTaTis Discovers Potent Inhibitor of Parkinson's Disease Gene Activity 2PHARMORX Security Introduces New Technology Solutions for Counterfeiting, Grey Market Diversion, Track & Trace 2PHARMORX Security Introduces New Technology Solutions for Counterfeiting, Grey Market Diversion, Track & Trace 3
(Date:4/15/2014)... CLEVELAND, Ohio (April 16, 2014)A new study from the ... vitamin D levels and menopause symptoms. The study was ... of The North American Menopause Society., The authors analyzed ... and a number of menopause symptoms, including hot flashes, ... women who participated in the calcium and vitamin D ...
(Date:4/15/2014)... in Greenbelt, Md., is home to hundreds of ... Goddard, some of the most cutting-edge Earth science ... that cutting-edge innovation has earned a Goddard scientist ... for Anthropology and Geography awards the Vega Medal ... shown excellence in the fields of physical geography, ...
(Date:4/15/2014)... Missouri researchers have previously shown that a genetic pre-disposition ... In a new study, Frank Booth, a professor in ... potential link between the genetic pre-disposition for high levels ... maturation occurs. , For his study, Booth selectively bred ... extreme laziness. Booth then put the rats in cages ...
Breaking Biology News(10 mins):Low Vitamin D may not be a culprit in menopause symptoms 2Goddard scientist receives Vega Medal from King of Sweden 2Genetic pre-disposition toward exercise and mental development may be linked 2
... dreaded disease in medieval Europe ?to fade from the ... disappeared there. , The reason seems to be, say ... London, that tuberculosis, a far more deadly disease, overtook ... based upon the examination of DNA from human remains ...
... Throughout the animal kingdom, rival males routinely challenge one ... collisions between bighorn rams to the ritualized wrestling matches ... reproductive success. , But now scientists studying a ... male cichlids can quickly become leading men without even ...
... provide some protection to the heart from injury even ... heart attack, Jefferson Medical College researchers report. , Walter ... in the Department of Medicine at Jefferson Medical College ... knew that the drug Darbepoietin alpha would protect the ...
Cached Biology News:Once-dreaded leprosy 'replaced' by tuberculosis, say researchers 2Sudden change in social status triggers genetic response in male fish, study finds 2Sudden change in social status triggers genetic response in male fish, study finds 3Sudden change in social status triggers genetic response in male fish, study finds 4Sudden change in social status triggers genetic response in male fish, study finds 5Sudden change in social status triggers genetic response in male fish, study finds 6
... end-users to be "a delight to use" ... microscopy and electronic imaging. With its ergonomic ... require much space and can easily be ... DM-BA300 combines Motic's own revolutionary Colour Corrected ...
Request Info...
When added to StemSep T Cell Enrichment cocktail, human TCRab TAC is designed to deplete human TCRab from samples to isolate gd T cells....
When added to either StemSep CD4+ or CD8+ T Cell Enrichment cocktails, human CD69 TAC is designed to deplete human CD69 from samples to isolate resting CD4+ or CD8+ T cells....
Biology Products: